Site icon The Invincible India

Startup Deep Dive : Foxtale — revenue grew 2.4x in FY25 but losses grew even faster

The Invincible India
The Invincible India Startup Deep Dive featured graphic for Foxtale.

In the financial year ended March 2025, Foxtale’s revenue from operations rose 2.4x to ₹199 crore (~$20.7 million), as reported by Entrackr from the Mumbai skincare brand’s regulatory filings. Its net loss grew even faster, up 38% to ₹73 crore in the same year — meaning the faster Foxtale sells serums and sunscreens, the more money it currently loses doing it.

That contradiction sits at the centre of one of India’s fastest-scaling direct-to-consumer skincare stories. Founded by a former investment banker who says she interviewed hundreds of Indian women before writing a single product brief, Foxtale has gone from a Chennai lab experiment to a brand fronted by Shah Rukh Khan in under five years — while still searching for the formula that turns growth into profit.

Quick facts

Company Foxtale (Foxtale Consumer Private Limited)
Founded Incorporated 5 May 2021 in Mumbai; R&D lab set up in Chennai in January 2021 (Tracxn legal-entity filing; Founder Thesis, June 2024)
Founder(s) Romita Mazumdar (Founder & CEO)
Businesses D2C skincare: serums, sunscreens, moisturisers, face washes, masks, sold via its own website, marketplaces and offline retail
Latest FY revenue ₹199 crore, operating revenue, FY25 (Entrackr, December 2025)
Latest FY profit/loss Net loss of ₹73 crore, FY25 (Entrackr, December 2025)
Listed Private — no IPO announced
Market value / last valuation ₹1,530 crore (~$180 million), post-Series C, January 2025 (Entrackr’s analysis of regulatory filings, April 2025)
Key shareholders Romita Mazumdar 34.38%; Z47 19.64%; Kae Capital 17.35%; Panthera Growth Partners 12.62%; KOSÉ Corporation 10% (Entrackr, April 2025)

What they do

Foxtale sells skincare, not cosmetics — serums, sunscreens, moisturisers, cleansers and masks built around active ingredients such as vitamin C, niacinamide and peptides, priced mostly in the ₹500–1,500 mid-premium band. Its customers are young, urban Indian women, largely aged 18 to 30, who have been priced out of imported dermatologist-grade brands but have outgrown mass-market drugstore skincare. The brand sells directly through foxtale.in, through marketplaces such as Amazon, Nykaa, Flipkart and Myntra, and, increasingly, through general trade and retail counters in more than ten cities (D2CX by Inc42, January 2025).

The origin

Romita Mazumdar did not start in skincare. She studied at UCLA, then worked in investment banking at Bank of America Merrill Lynch, first covering US consumer-tech names such as Airbnb and Uber before moving to the bank’s India desk in 2018 to work on deals involving Swiggy and Zoomcar. That move taught her, in her words, that Indian and American consumer businesses were not the same animal (Founder Thesis, June 2024). Wanting to understand India’s consumer ecosystem more deeply, she joined A91 Partners, a growth-equity fund founded by former Sequoia India partners, as an analyst covering Series B and C consumer companies.

It was there, on weekends and evenings, that she began the research that became Foxtale: structured interviews with more than 900 Indian women about their skincare routines and frustrations, a number she has cited at 937 in the same interview. Three things kept coming up — that most products did not visibly solve the specific skin problem they promised, that Indian buyers wanted fast, visible results, and that most “clean beauty” brands were chasing ingredient trends rather than consistent efficacy. She set up an R&D lab in Chennai in January 2021, funding early formulation work from her own savings before the company was even incorporated, and Foxtale Consumer Private Limited was registered on 5 May 2021 (Tracxn legal-entity filing, accessed September 2026).

The struggle years

The company’s first year was also the country’s second Covid-19 wave. With manufacturing and formulation based in Chennai and Mazumdar working out of Mumbai, national lockdowns meant she could not visit the lab in person; each new formulation had to be couriered to her, adding roughly a week to every iteration cycle at a stage when speed mattered most (Founder Thesis, June 2024). Foxtale’s institutional funding did not arrive until an undisclosed seed round led by Matrix Partners India and Kae Capital in August 2021, months after incorporation, which meant the earliest R&D was self-funded (Entrackr, June 2022).

The deeper strain came later, once the brand had customers. Losses grew faster than the company could raise comfort around them: a ₹19 crore net loss in FY23 widened to ₹55 crore in FY24 and then to ₹73 crore in FY25, even as revenue climbed (SiliconIndia, January 2025; Entrackr, December 2025). Entrackr’s own reporting flagged the pace of the resulting fundraising treadmill: Foxtale closed roughly $48 million across two rounds — its Series B and Series C — within about seven months of each other between mid-2024 and early 2025, an unusually tight cycle for an Indian D2C brand still posting operating losses (Entrackr, April 2025). Running a mid-premium skincare brand at this speed, in other words, has meant raising money almost as often as it has meant launching products.

The turning point

The moment that gave Foxtale credibility with both investors and consumers was not a funding round but a single introduction. Mazumdar has described searching through LinkedIn for veteran cosmetic formulators and reaching Dr Ramesh Surin Narayanan, a formulation scientist who had worked at Hindustan Unilever — credited in her account with the Fair & Lovely (now Glow & Lovely) formulation — and later at Himalaya. Her pitch, as she recounts it: “You help me solve the formulation part, I’ll help you solve the testing.” He agreed, and Foxtale’s R&D effort went from a founder’s hypothesis to a lab with a credentialed formulator behind it (Founder Thesis, June 2024). On the numbers, that single relationship helped take the brand from a pre-revenue idea in 2021 to ₹13.8 crore in FY23 revenue and, within two more years, to ₹199 crore in FY25 — a roughly fourteen-fold increase in operating revenue in two fiscal years (Inc42, March 2024; Entrackr, December 2025).

The money behind it

Foxtale has raised money in five disclosed institutional rounds since 2021, all from the same core investor group expanding its stake over time:

Adding the disclosed tranches puts total funding at roughly $66 million before the undisclosed seed amount; Tracxn separately pegs cumulative funding at $56.8 million as of September 2026, a lower figure likely reflecting different FX conversions or an incomplete count of the seed round — both figures point to a company that has now raised well over $50 million. Each backer changed something specific: Matrix Partners India and Kae Capital funded the founding thesis before Foxtale had meaningful revenue; Panthera Growth Partners, a growth-stage investor, led the rounds that took the company from ₹14 crore to ₹83 crore in operating revenue; and KOSÉ Corporation, a listed Japanese beauty conglomerate, brought both capital and formulation and manufacturing relationships when it led the Series C. Post-Series C, Foxtale’s valuation stood at ₹1,530 crore (~$180 million), up from ₹795 crore (~$93.5 million) before the round — a valuation Entrackr calculated from the Series C share issue price disclosed in regulatory filings, not from a company statement (Entrackr, April 2025).

How it makes money

Foxtale earns the way most D2C skincare brands do: it manufactures through contract formulators, sells at a marked-up retail price across its own website, marketplaces and retail counters, and spends heavily on performance and celebrity marketing to acquire and retain customers. The specifics from its FY25 filings, as reported by Entrackr:

The part people get wrong about a brand like this is assuming the margin sits in the product. It largely does not — cost of materials is only about a third of revenue. The bigger swing factor is marketing spend: advertising alone consumed 53% of FY25 revenue, and the entire loss narrows or widens with how efficiently that spend converts to sales. Foxtale’s own reported improvement — from ₹1.67 to ₹1.40 spent per rupee earned — is the clearest sign yet that the model can, in principle, reach breakeven if advertising efficiency keeps improving rather than if the company merely sells more.

The numbers

Three consecutive years of filings show revenue scaling fast while losses widen in absolute terms, even as they shrink as a share of revenue:

Fiscal year Operating revenue (₹ crore) Net loss (₹ crore)
FY23 13.8 19
FY24 83 55
FY25 199 73

(Inc42, March 2024, for FY23; SiliconIndia, January 2025, and Entrackr, December 2025, for FY24 and FY25.) Cash and bank balances have grown alongside the losses — from ₹43–44 crore at the end of FY24 to ₹166 crore at the end of FY25 — because each funding round has outpaced the cash burn, not because the business itself is throwing off cash (Entrackr, December 2025).

Where the money comes from

Foxtale’s revenue is split across three channels, based on figures tied to FY24:

The surprise is less the channel mix than the direction of travel: a brand born entirely on its own website and Instagram is now pushing hardest into general trade — the unglamorous business of stocking neighbourhood chemists and beauty stores — because that is where the next layer of Indian skincare buyers, particularly outside the top metros, still shop.

The risks

The takeaway

Foxtale’s most transferable lesson is not about skincare at all — it is about how long a founder can keep substituting research rigour for capital before the business needs capital anyway. Mazumdar’s edge at the start was patience: hundreds of customer interviews, a 12-to-18-month product development cycle, and a formulator recruited one LinkedIn message at a time, all before the brand had meaningful revenue. That discipline built genuine credibility in a market full of trend-chasing brands. But scaling that credibility into a mainstream business has meant doing the opposite — spending on celebrity endorsement and paid marketing faster than revenue can cover it, and returning to investors every few months to fund the gap. The two instincts are not automatically compatible, and Foxtale’s next few fiscal years will show whether the same founder who built trust through patience can now build a profit line through speed.

Frequently asked questions

What does Foxtale sell?

Foxtale is a direct-to-consumer skincare brand selling serums, sunscreens, moisturisers, cleansers and masks built around specific active ingredients, priced mostly in the ₹500–1,500 range, sold through its own website, marketplaces and a growing offline retail footprint.

Who founded Foxtale and when?

Romita Mazumdar, a former investment banker and venture capital analyst, founded Foxtale; the company, Foxtale Consumer Private Limited, was incorporated in Mumbai on 5 May 2021, after R&D work began in a Chennai lab in January 2021.

How much funding has Foxtale raised, and at what valuation?

Foxtale has raised money across five disclosed rounds — a 2021 seed round, a $4 million pre-Series A in 2022, a ₹119 crore Series A in March 2024, an $18 million Series B in June 2024, and a $30 million Series C in January 2025 led by KOSÉ Corporation — taking cumulative funding to more than $50 million. Its post-Series C valuation was calculated by Entrackr at ₹1,530 crore (~$180 million) as of January 2025, based on regulatory filings.

Is Foxtale profitable?

No. Foxtale reported a net loss of ₹73 crore in FY25 on operating revenue of ₹199 crore, wider in absolute terms than its ₹55 crore loss in FY24, though the loss has been shrinking as a share of revenue as the business scales.

Who are Foxtale’s main competitors?

In India’s mid-premium, ingredient-led skincare segment, Foxtale’s closest competitors include Minimalist, Deconstruct, Dr Sheth’s, Pilgrim and mCaffeine, all positioned around active-ingredient transparency rather than legacy branding.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.

Exit mobile version